NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women

Bone

Volumn 42, Issue 1, 2008, Pages 16-18

  Delmas, Pierre D ^a   Siris, Ethel S ^b  

^a UNIVERSITÉ DE LYON   (France)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

AGE DISTRIBUTION; BODY MASS; BONE DENSITY; COST EFFECTIVENESS ANALYSIS; EDITORIAL; FRAGILITY FRACTURE; HEALTH CARE ORGANIZATION; HUMAN; NATIONAL HEALTH SERVICE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SPONDYLITIS; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; FEMALE; FRACTURES, BONE; HEALTH PLANNING GUIDELINES; HUMANS; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 37349045601     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.10.020     Document Type: Editorial

References (23)

1. Kanis J.A., Adams J., Borgström F., Cooper C., Jönsson B., Preedy D., and Selby P. The cost effectiveness of alendronate in the management of osteoporosis. Bone 42 (2008) 4-15
2. National Institute for Health and Clinical Excellence. Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (June 2007), NICE, London. http://www.nice.org.uk www.nice.org.uk
3. National Institute for Health and Clinical Excellence. Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (June 2007), NICE, London. http://www.nice.org.uk www.nice.org.uk
4. Royal College of Physicians. Osteoporosis: clinical guidelines for the prevention and treatment (1999), Royal College of Physicians, London, UK
5. Royal College of Physicians, and Bone and Tooth Society of Great Britain. Update on pharmacological interventions and an algorithm for management (2000), Royal College of Physicians, London, UK
6. Royal College of Physicians. Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Royal College of Physicians 2002, London, UK.
7. Kanis J.A., Delmas P., Burckhardt P., Cooper C., and Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European foundation for osteoporosis and bone disease. Osteoporos Int 7 (1997) 390-406
8. European Community. Report on osteoporosis in the European Community (1998), EC, Strasbourg
9. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis (2003), National Osteoporosis Foundation, Washington, DC
10. Kanis J.A., Borgstrom F., Johnell O., and Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15 (2004) 862-871
11. Kanis J.A., Borgstrom F., Johnell O., Oden A., Sykes D., and Jonsson B. Cost-effectiveness of raloxifene in the UK. An economic evaluation based on the MORE study. Osteoporos Int 16 (2005) 15-25
12. Strom O., Borgstrom F., Sen S.S., Boonen S., Haentjens P., Johnell O., et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 18 (2007) 1047-1061
13. Drummond M.F., Sculpher G.W., Torrance B., O'Brien G.L., and Stoddart J. Methods for the economic evaluation of health care programmes. 3rd ed (2005), Oxford University Press, Oxford
14. National Institute for Health and Clinical Excellence. Final appraisal determination. Statins for the prevention of cardiovascular events (2006), NICE, London, UK. http://www.nice.org.uk www.nice.org.uk. accessed 1st Feb 2007
15. Zethraeus N., Borgstrom F., Strom O., Kanis J.A., and Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int 18 (2007) 9-23
16. National Institute for Clinical Excellence. Guide to the methods of technology appraisal (2004), Abbo Litho Sales, London
17. National Institute for Health and Clinical Excellence. Appraisal consultation document. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (Feb 2007), NICE, London. http://www.nice.org.uk www.nice.org.uk
18. National Institute for Health and Clinical Excellence. Appraisal consultation document. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (Feb 2007), NICE, London. http://www.nice.org.uk www.nice.org.uk
19. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359 (2002) 1929-1936
20. Kanis J.A., Borgstrom F., De Laet C., Johansson H., Johnell O., Jonsson B., et al. Assessment of fracture risk. Osteoporos Int 16 (2005) 581-589
21. Kanis J.A., Black D., Cooper C., Dargent P., Dawson-Hughes B., De Laet C., et al. Tenenhouse A on behalf of the International Osteoporosis Foundation and National Osteoporosis Foundation. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13 (2002) 527-536
22. Siris E.S., Miller P.D., Barrett-Connor E., Faulkner K.G., Wehren L.E., Abbott T.A., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286 (2001) 2815-2822
23. Sornay-Rendu E., Munoz F., Garnero P., Duboeuf F., and Delmas P.D. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20 (2005) 1813-1819